Duell J, Maddocks KJ, Gonzalez-Barca E, Jurczak W, et al. Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma. Haematologica 2021 Aug 19. doi: 10.3324/haematol.2021.279802.
PMID: 34407608